Klinická farmakologie a farmacie – 3/2020

www.klinickafarmakologie.cz  / KlinFarmakol Farm2020; 34(3): 135–141 / KLINICKÁ FARMAKOLOGIE A FARMACIE 141 PŘEHLEDOVÉ ČLÁNKY Současný pohled na podávání intravenózních imunoglobulinů u pacientů s toxickou epidermální nekrolýzou venous immunoglobulin. Science 1998; 282(5388): 490–493. 38. Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epi‑ dermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol 2012; 67(4): 630–635. 39. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermalnecrolysistreatedwith intravenoushigh-dose immu‑ noglobulins: our experience. Dermatology 2001; 203(1): 45–49. 40. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47(4): 548–552. 41. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglo‑ bulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Der‑ matol 2003; 139(1): 33–36. 42. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglo‑ bulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta DermVenereol 2003; 83(6): 430–432. 43. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of in‑ travenous immunoglobulin for the treatment of toxic epider‑ mal necrolysis using Scorten: The University of Miami Expe‑ rience. Arch Dermatol 2003; 139(1): 39–43. 44. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE. Treatment of toxic epidermal necrolysis with high-dose intra‑ venous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139(1): 26–32. 45. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el-A, Nazeha el-B. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004; 43(11): 847–851. 46. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobu‑ lin make a difference? J Burn Care Rehabil 2004; 25(1): 81–88. 47. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epi‑ dermal necrolysis. J Burn Care Rehabil 2004; 25(3): 246–255. 48. Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, Koh JK. Toxic epidermal necrolysis: analysis of clinical course and SCOR‑ TEN-basedcomparisonofmortalityrateandtreatmentmodali‑ ties inKoreanpatients.ActaDermVenereol2005;85(6):497–502. 49. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with se‑ vere toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58(4): 504–510. 50. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Effi‑ cacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled stu‑ dy. Indian J Dermatol Venereol Leprol 2005; 71(6): 398–400. 51. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epi‑ dermal necrolysis: an Asian series. J Dermatol 2005; 32(1): 1–6. 52. Yeung CK, Lam LK, Chan HH. The timing of intravenous im‑ munoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30(5): 600–602. 53. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond) 2005; 19(8): 846–853. 54. Imahara SD, Holmes JH 4th, Heimbach DM, Engrav LE, Honari S, Klein MB, Gibran NS. SCORTEN overestimates mor‑ tality in the setting of a standardized treatment protocol. J Burn Care Res 2006; 27(3): 270–275. 55. Paquet P, Kaveri S, Jacob E, Pirson J, Quatresooz P, Piérard GE. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006; 15(5): 381–386. 56. Gravante G, Delogu D, Marianetti M, Trombetta M, Espo‑ sito G, Montone A. Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci 2007; 11(2): 119–127. 57. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglo‑ bulins and topical conservative approach. A retrospective analysis. Burns 2007; 33(4): 452–459. 58. CartottoR,MayichM,NickersonD,GomezM.SCORTENaccu‑ ratelypredictsmortalityamongtoxicepidermalnecrolysispati‑ entstreated inaburncenter.JBurnCareRes2008;29(1):141–146. 59. Dorafshar AH, Dickie SR, Cohn AB, Aycock JK, O’Connor A, Tung A, Gottlieb LJ. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Recon‑ str Surg 2008; 122(1): 154–160. 60. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Moc‑ kenhaupt M. Effects of treatments on the mortality of Ste‑ vens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospecti‑ ve EuroSCAR Study. J Am Acad Dermatol 2008; 58(1): 33–40. 61. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, Lim R, Papini R, Moiemen N, Lewis H. Toxic epidermal necrolysis: retrospective analysis of 21 consecu‑ tive cases managed at a tertiary centre. Clin Exp Dermatol 2010; 35(8): 853–862. 62. Atzori L, Pinna AL, Mantovani L, Ferreli C, Pau M, Mular‑ gia M, Aste N. Cutaneous adverse drug reactions to allopu‑ rinol: 10 year observational survey of the dermatology de‑ partment–Cagliari University (Italy). J Eur Acad Dermatol Venereol 2012; 26(11): 1424–1430. 63. Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necro‑ lysis: performance of SCORTEN and the score-based com‑ parison of the efficacy of corticosteroid therapy and intra‑ venous immunoglobulin combined therapy in China. J Burn Care Res 2012; 33(6): e295–e308. 64. Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ra‑ vidran S, Divakaran MV, Skaria L, Kurien G. Low dose intra‑ venous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled stu‑ dy of 36 cases. Indian J Dermatol Venereol Leprol 2013; 79(4): 506–511. 65. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of in‑ travenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a speciali‑ zed centre. Br J Dermatol 2013; 169(6): 1304–1309. 66. Aihara M, Kano Y, Fujita H, Kambara T, Matsukura S, Ka‑ tayama I, Azukizawa H, Miyachi Y, Endo Y, Asada H, Miyaga‑ wa F, Morita E, Kaneko S, Abe R, Ochiai T, Sueki H, Watanabe H, Nagao K, Aoyama Y, Sayama K, Hashimoto K, Shiohara T. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necroly‑ sis. J Dermatol 2015; 42(8): 768–777. 67. Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necroly‑ sis: a 20-year single-center experience. Int J Dermatol 2015; 54(8): 978–984. 68. Yang L, Shou YH, Li F, Zhu XH, Yang YS, Xu JH. Retrospec‑ tive study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns 2019; S0305- 4179(19)30459-0. 69. Krajewski A, Mazurek MJ, Mlynska-Krajewska E, Piorun K, Knakiewicz M, Markowska M. Toxic epidermal necroly‑ sis therapy with TPE and IVIG-10 years of experience of the Burns Treatment Center. J Burn Care Res 2019; 40(5): 652–657. 70. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic immunomo‑ dulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analy‑ sis. JAMA Dermatol 2017; 153(6): 514–522. 71. Borilova Linhartova P, Gachova D, Lipovy B. Responsi‑ veness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. J Dermatol 2020. doi: 10.1111/1346-8138.15583.